150 related articles for article (PubMed ID: 9663361)
21. A comparison of the efficacy and tolerability of dorzolamide and acetazolamide as adjunctive therapy to timolol. Oral to Topical CAI Study Group.
Hutzelmann JE; Polis AB; Michael AJ; Adamsons IA
Acta Ophthalmol Scand; 1998 Dec; 76(6):717-22. PubMed ID: 9881560
[TBL] [Abstract][Full Text] [Related]
22. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial.
Shedden A; Adamsons IA; Getson AJ; Laurence JK; Lines CR; Hewitt DJ; Ho TW
Graefes Arch Clin Exp Ophthalmol; 2010 Dec; 248(12):1757-64. PubMed ID: 20437244
[TBL] [Abstract][Full Text] [Related]
23. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group.
Silver LH
Am J Ophthalmol; 1998 Sep; 126(3):400-8. PubMed ID: 9744373
[TBL] [Abstract][Full Text] [Related]
24. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients.
Harris A; Arend O; Chung HS; Kagemann L; Cantor L; Martin B
Ophthalmology; 2000 Mar; 107(3):430-4. PubMed ID: 10711877
[TBL] [Abstract][Full Text] [Related]
25. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group.
Lass JH; Khosrof SA; Laurence JK; Horwitz B; Ghosh K; Adamsons I
Arch Ophthalmol; 1998 Aug; 116(8):1003-10. PubMed ID: 9715679
[TBL] [Abstract][Full Text] [Related]
26. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension.
Sezgin Akçay Bİ; Güney E; Bozkurt KT; Unlü C; Akçali G
J Ocul Pharmacol Ther; 2013 Dec; 29(10):882-6. PubMed ID: 24180628
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and side effects of latanoprost monotherapy compared to adding dorzolamide to timolol in patients with glaucoma and ocular hypertension--a three-month randomised study. Spanish Latanoprost Study Group.
García Sanchez J
Eur J Ophthalmol; 2000; 10(3):198-204. PubMed ID: 11071026
[TBL] [Abstract][Full Text] [Related]
29. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure.
Stewart WC; Sharpe ED; Harbin TS; Pastor SA; Day DG; Holmes KT; Stewart JA
Am J Ophthalmol; 2000 Jun; 129(6):723-7. PubMed ID: 10926979
[TBL] [Abstract][Full Text] [Related]
30. Results of the European Glaucoma Prevention Study.
Miglior S; Zeyen T; Pfeiffer N; Cunha-Vaz J; Torri V; Adamsons I;
Ophthalmology; 2005 Mar; 112(3):366-75. PubMed ID: 15745761
[TBL] [Abstract][Full Text] [Related]
31. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle glaucoma.
Ormrod D; McClellan K
Drugs Aging; 2000 Dec; 17(6):477-96. PubMed ID: 11200308
[TBL] [Abstract][Full Text] [Related]
32. A clinical trial of MK-507, Trusopt, for raised intraocular pressure--the Australian experience.
Gillies WE; Brooks AM
Aust N Z J Ophthalmol; 1996 May; 24(2):111-5. PubMed ID: 9199740
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors.
Sugrue MF
Prog Retin Eye Res; 2000 Jan; 19(1):87-112. PubMed ID: 10614682
[TBL] [Abstract][Full Text] [Related]
34. Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. ALPHAGAN/XALATAN Study Group.
Simmons ST; Samuelson TW
Clin Ther; 2000 Apr; 22(4):388-99. PubMed ID: 10823361
[TBL] [Abstract][Full Text] [Related]
35. Tolerability and efficacy of dorzolamide versus acetazolamide added to timolol.
Stewart WC; Halper LK; Johnson-Pratt L; Polis A; Hartenbaum D
J Ocul Pharmacol Ther; 2002 Jun; 18(3):211-20. PubMed ID: 12099542
[TBL] [Abstract][Full Text] [Related]
36. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. Dorzolamide Safety Study Group.
Adamsons IA; Polis A; Ostrov CS; Boyle JE
J Glaucoma; 1998 Dec; 7(6):395-401. PubMed ID: 9871861
[TBL] [Abstract][Full Text] [Related]
37. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
[TBL] [Abstract][Full Text] [Related]
38. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma.
Feldman RM; Stewart RH; Stewart WC; Jia G; Smugar SS; Galet VA
Curr Med Res Opin; 2008 Aug; 24(8):2403-12. PubMed ID: 18627642
[TBL] [Abstract][Full Text] [Related]
39. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability.
Sall KN; Greff LJ; Johnson-Pratt LR; DeLucca PT; Polis AB; Kolodny AH; Fletcher CA; Cassel DA; Boyle DR; Skobieranda F
Ophthalmology; 2003 Mar; 110(3):615-24. PubMed ID: 12623832
[TBL] [Abstract][Full Text] [Related]
40. The dorzolamide/timolol combination versus timolol plus pilocarpine: patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group.
Sverrisson T; Gross R; Pearson J; Rusk C; Adamsons I
J Glaucoma; 1999 Oct; 8(5):315-24. PubMed ID: 10529932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
